Peptides / Recovery and repair

Conjugate · 34 amino acids

Palopegteriparatide

ApprovedNot banned in sport

Palopegteriparatide (Yorvipath) is a prodrug that releases teriparatide, approved in the US and EU for hypoparathyroidism in adults. Studies in people tested it on blood calcium, kidney function, supplement needs and quality of life, and tracked side effects. PepBank shows 193 results on palopegteriparatide from 24 studies in people, and 17 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as TransCon PTH, Yorvipath

34 amino acids, from first to last1 changed amino acid

Evidence level: Some studies in people193 of 210 results come from studies in people.

Results in people

193

92% of 210 results

Results in animals

8% of 210 results

Results in lab cells

0% of 210 results

From computer models

0% of 210 results

Overview

Palopegteriparatide at a glance

What it is	Conjugate, 34 amino acids
Approval	Approved in the US and EU (Yorvipath, 2024)
In sport	Not listed as banned by WADA
Studies	25 studies with results. All of them gave palopegteriparatide, with 210 results. 193 in people17 in animals
Best study in people	Randomized controlled trial with 82 people (2023)
Clinical trials	10 registered: 5 active or planned, 2 with posted results
Community use	Treatment of hypoparathyroidism in adults with prescribed Yorvipath

The science

What is palopegteriparatide?

Palopegteriparatide is a prodrug that releases PTH(1-34), or teriparatide.

Amino acids in one chain

The history of palopegteriparatide

2019
The oldest paper on palopegteriparatide in PepBank is from 2019.
2019August
A registered trial of palopegteriparatide started (NCT04009291).
2024August
FDA approved Yorvipath for treatment of hypoparathyroidism in adults.

Palopegteriparatide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 34 amino acidsFrom the first amino acid to the last

S1VS−EI5QLMHN10LG+KHL15NSM−E+R20V−EWL+R25+K+KLQ−D30VHNF

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Palopegteriparatide is a conjugate of 34 amino acids, with no ring, 1 changed amino acid.

CAS number

2222514-07-8

Target

Parathyroid hormone 1 receptor (gene PTH1R): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

ChEMBL CHEMBL5095475, UNII G2N64C3385

See charge, composition and 3D structure on the Scientific page

The evidence

What palopegteriparatide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people193 of 210 results come from studies in people.

Salt, water and minerals

50 results · 43 in people · 7 animal

In hypoparathyroidism, 79% receiving TransCon PTH versus 5% receiving placebo met the composite primary endpoint at week 26. Journal of bone and mineral research, 2023

Top results

In hypoparathyroidism, 79% receiving TransCon PTH versus 5% receiving placebo met the composite primary endpoint at week 26. (Journal of bone and mineral research, 2023)
In adults with hypoparathyroidism, mean serum calcium at Week 26 was 8.9 mg/dL with TransCon PTH versus 8.2 mg/dL with placebo. (Journal of the Endocrine Society, 2022)
After 26 weeks of palopegteriparatide, 92% of Japanese participants achieved the combined calcium and supplement-independence endpoint. (Endocrine journal, 2026)

Hormones

26 results · 26 in people

Among adults remaining in the palopegteriparatide extension at week 52, 95% no longer required conventional therapy as defined in the study. Advances in therapy, 2024

Top results

Among adults remaining in the palopegteriparatide extension at week 52, 95% no longer required conventional therapy as defined in the study. (Advances in therapy, 2024)
In adults with hypoparathyroidism, 93% receiving TransCon PTH achieved independence from conventional therapy. (Journal of the Endocrine Society, 2022)
In hypoparathyroidism, 93% receiving TransCon PTH achieved independence from conventional therapy. (Journal of bone and mineral research, 2023)

Daily life and fitness

24 results · 24 in people

In hypoparathyroidism, TransCon PTH improved all key secondary HPES domain scores versus placebo. Journal of bone and mineral research, 2023

Top results

In hypoparathyroidism, TransCon PTH improved all key secondary HPES domain scores versus placebo. (Journal of bone and mineral research, 2023)
Among adults with pre-trial muscle twitching, 100% reported improvement with TransCon PTH. (Journal of patient-reported outcomes, 2024)
In hypoparathyroidism, TransCon PTH improved physical functioning scores versus placebo. (Journal of bone and mineral research, 2023)

Kidneys and bladder

28 results · 23 in people · 5 animal

In adults with hypoparathyroidism, urine calcium fell from 390 to 220 mg/24-hour with TransCon PTH and from 329 to 292 with placebo. Journal of the Endocrine Society, 2022

Top results

In adults with hypoparathyroidism, urine calcium fell from 390 to 220 mg/24-hour with TransCon PTH and from 329 to 292 with placebo. (Journal of the Endocrine Society, 2022)
In adults with hypoparathyroidism receiving TransCon PTH, urine calcium decreased from baseline by Week 26. (The Journal of clinical endocrinology and metabolism, 2022)
In adults with hypoparathyroidism receiving TransCon PTH, urine calcium decreased from baseline by Week 26. (Journal of the Endocrine Society, 2021)

Bones and joints

13 results · 13 in people

In healthy adults receiving daily TransCon PTH for 10 days, a bone formation marker, bone-specific alkaline phosphatase, did not increase. Journal of bone and mineral research, 2020

Top results

In healthy adults receiving daily TransCon PTH for 10 days, a bone formation marker, bone-specific alkaline phosphatase, did not increase. (Journal of bone and mineral research, 2020)
In adults with hypoparathyroidism, bone density decreased from elevated baseline levels during palopegteriparatide treatment. (Journal of bone and mineral research, 2026)
In healthy adults receiving daily TransCon PTH for 10 days, the bone formation marker P1NP did not increase. (Journal of bone and mineral research, 2020)

Memory and thinking

5 results · 5 in people

Among adults with pre-trial difficulty finding words, 86.7% reported improvement with TransCon PTH. Journal of patient-reported outcomes, 2024

Top results

Among adults with pre-trial difficulty finding words, 86.7% reported improvement with TransCon PTH. (Journal of patient-reported outcomes, 2024)
Among adults with pre-trial concentration difficulty, 93.3% reported improvement with TransCon PTH. (Journal of patient-reported outcomes, 2024)
Among adults with pre-trial memory difficulty, 92.9% reported improvement with TransCon PTH. (Journal of patient-reported outcomes, 2024)

All 25 palopegteriparatide studies by area Open the Scientific page

Key palopegteriparatide studies

Studies in people come first, then studies in animals and in the lab.

People
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
Khan et al. 2023 · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 82 people · cited by 81
7 results
People
OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium
2022 · Journal of the Endocrine Society · 82 people · cited by 0
16 results
People
Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial
Ashida et al. 2026 · Endocrine journal · 13 people · cited by 1
4 results
People
A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults
Karpf et al. 2020 · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · cited by 46
14 results
People
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
Rejnmark et al. 2024 · Advances in therapy · 82 people · cited by 33
8 results

All 25 Palopegteriparatide studies

Palopegteriparatide clinical trials

ClinicalTrials.gov lists 10 trials of palopegteriparatide. 5 are active or planned, and 2 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Phase 3completed84 people

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Phase 3completed81 people

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Phase 3recruiting36 planned

All 3 Palopegteriparatide trials

Status and safety

Is palopegteriparatide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Yorvipath, 2024). The FDA label for Yorvipath says: “Treatment of hypoparathyroidism in adults” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Palopegteriparatide side effects and safety

PepBank has 49 safety results from studies of palopegteriparatide. 48 of them come from studies in people.

Safety results from studies (49)

In hypoparathyroidism, adverse events occurred in 82% receiving TransCon PTH versus 100% receiving placebo. (Journal of bone and mineral research, 2023)
In adults with hypoparathyroidism receiving TransCon PTH, no treatment-related serious adverse events occurred. (The Journal of clinical endocrinology and metabolism, 2022)
In healthy adults, TransCon PTH was generally well tolerated. (Journal of bone and mineral research, 2020)
In adults with hypoparathyroidism, no kidney stones were reported with palopegteriparatide through week 52. (Advances in therapy, 2024)
Most adverse events during palopegteriparatide treatment were mild or moderate. (Journal of bone and mineral research, 2026)
Adverse events during palopegteriparatide treatment were mild to moderate in Japanese adults with hypoparathyroidism. (Endocrine journal, 2026)
In adults with hypoparathyroidism, TransCon PTH was generally well tolerated. (Journal of the Endocrine Society, 2022)
In adults with hypoparathyroidism receiving TransCon PTH, most adverse events were mild and unrelated to study drug. (Journal of the Endocrine Society, 2022)
In adults with hypoparathyroidism receiving TransCon PTH, no treatment-related serious adverse events occurred. (Journal of the Endocrine Society, 2021)
In adults with hypoparathyroidism receiving palopegteriparatide, adverse events were mostly mild and transient. (European journal of endocrinology, 2026)
In patients switching to TransCon PTH, the treatment change was linked to mild or moderate adverse events in 24/40 patients. (Journal of the Endocrine Society, 2025)
In adults with hypoparathyroidism, no new safety signals appeared with up to 12 months of palopegteriparatide treatment. (Endocrine practice, 2025)
After palopegteriparatide discontinuation, a woman with hypoparathyroidism resumed calcium doses similar to those before hormone therapy. (JCEM case reports, 2026)
In a boy with postsurgical hypocalcemia, palopegteriparatide was well tolerated. (European journal of endocrinology, 2026)
A patient reported no adverse events after transition to palopegteriparatide. (JCEM case reports, 2026)
After palopegteriparatide discontinuation, a man restarted calcitriol at double his pre-palopegteriparatide dose. (Calcified tissue international, 2025)
In the hypoparathyroidism TransCon PTH trial, no study drug-related withdrawals occurred. (Journal of bone and mineral research, 2023)
In adults with hypoparathyroidism receiving TransCon PTH, no treatment-related severe adverse events occurred. (The Journal of clinical endocrinology and metabolism, 2022)
In healthy adults receiving TransCon PTH, no drug-related serious adverse events occurred. (Journal of bone and mineral research, 2020)
In healthy adults receiving TransCon PTH, all adverse events were temporary. (Journal of bone and mineral research, 2020)
In healthy adults receiving TransCon PTH, higher doses produced modest hypercalcemia. (Journal of bone and mineral research, 2020)
No new safety signals were reported during palopegteriparatide treatment. (Journal of bone and mineral research, 2026)
No treatment-related kidney stones were reported during palopegteriparatide treatment. (Journal of bone and mineral research, 2026)
No adverse event caused participants to stop palopegteriparatide treatment. (Endocrine journal, 2026)

See every safety result on the Scientific page

Doses studied (9 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
initially 18 μg/d, titrated	Human	human	Not reported	26 weeks	Randomized trial in people · n = 82	Khan 2023
18 mcg/d	Human	human	Not reported	26 weeks	Randomized trial in people · n = 82	2022
15, 18, or 21 mcg/d (or placebo) for 4 weeks, then titrated to maintain normocalcemia	Human	human	Not reported	Not reported	Trial in people without random groups · n = 58	2022
15, 18, or 21 µg PTH(1-34)/day for 4 weeks, then titrated 6-60 µg PTH(1-34)/day in a 22-week extension	Human	human	Not reported	Not reported	Trial in people without random groups · n = 44	Khan 2022
titrated 6–30 µg PTH(1–34)/day	Human	human	Not reported	Not reported	Trial in people without random groups · n = 44	Rubin 2021
12 to 33 µg/day	Human	human	Not reported	Not reported	Trial in people without random groups	Khan 2026
15, 18, or 21 µg/day	Human	human	Not reported	4 weeks	Trial in people without random groups	Rubin 2021
initially 18 µg, individually adjusted	Human	human	Not reported	Not reported	Observational study · n = 40	Siggelkow 2025
recommended starting dose 18 μg/day, titrated	Human	human	Not reported	Not reported	Observational study	Graham 2025

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Treatment of hypoparathyroidism in adults with prescribed YorvipathS1

Reported regimens

Regimens that community sources report for Palopegteriparatide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Starting Yorvipath treatment in adults with hypoparathyroidism using the approved solution in a single-patient-use prefilled penOfficial label dosing of an approved product	subcutaneous injection	18 mcg per dose	once daily	Not stated	Single official US label source.	S1

Cautions

The label warns about serious hypocalcemia and hypercalcemia. Calcium monitoring guides treatment.S1

Status notes

Yorvipath has EU authorisation for hormone replacement therapy in adults with chronic hypoparathyroidism.S2

Community sources

S1Yorvipath US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This record contains one selected US label starting regimen. It does not establish community practice. No independent non-vendor community regimen is verified here. The full label specifies titration, supplement adjustments, administration, interruptions, and additional safety conditions.

Questions and more

Ask a question about palopegteriparatide

The answer links to every study it uses.

What does the evidence say about palopegteriparatide?Is palopegteriparatide tested in people?Compare with Teriparatide (PTH 1-34)Compare with Calcitonin-salmon

Sources

Database: PepBank data for palopegteriparatide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about palopegteriparatide

Palopegteriparatide

ApprovedNot banned in sport

Also known as TransCon PTH, Yorvipath

What it is

Conjugate, 34 amino acids

Approval

Approved in the US and EU (Yorvipath, 2024)

In sport

Not listed as banned by WADA

Studies

25 studies with results. All of them gave palopegteriparatide, with 210 results.
193 in people17 in animals

Best study in people

Randomized controlled trial with 82 people (2023)

Clinical trials

10 registered: 5 active or planned, 2 with posted results

Community use

Treatment of hypoparathyroidism in adults with prescribed Yorvipath

Dose as reported

Class

Species

Route

Duration

Design

Source

initially 18 μg/d, titrated

Human

human

Not reported

26 weeks

Randomized trial in people · n = 82

Khan 2023

18 mcg/d

Human

human

Not reported

26 weeks

Randomized trial in people · n = 82

2022

15, 18, or 21 mcg/d (or placebo) for 4 weeks, then titrated to maintain normocalcemia

Human

human

Not reported

Trial in people without random groups · n = 58

2022

15, 18, or 21 µg PTH(1-34)/day for 4 weeks, then titrated 6-60 µg PTH(1-34)/day in a 22-week extension

Human

human

Not reported

Trial in people without random groups · n = 44

Khan 2022

titrated 6–30 µg PTH(1–34)/day

Human

human

Not reported

Trial in people without random groups · n = 44

Rubin 2021

12 to 33 µg/day

Human

human

Not reported

Trial in people without random groups

Khan 2026

15, 18, or 21 µg/day

Human

human

Not reported

4 weeks

Trial in people without random groups

Rubin 2021

initially 18 µg, individually adjusted

Human

human

Not reported

Observational study · n = 40

Siggelkow 2025

recommended starting dose 18 μg/day, titrated

Human

human

Not reported

Observational study

Graham 2025

Context

Route

Amount

How often

How long

Agreement

Sources

Starting Yorvipath treatment in adults with hypoparathyroidism using the approved solution in a single-patient-use prefilled penOfficial label dosing of an approved product

subcutaneous injection

18 mcg per dose

once daily

Not stated

Single official US label source.

Palopegteriparatide

Palopegteriparatide at a glance

What is palopegteriparatide?

The history of palopegteriparatide

Palopegteriparatide structure and chemistry

What palopegteriparatide studies show

Salt, water and minerals

Hormones

Daily life and fitness

Kidneys and bladder

Bones and joints

Memory and thinking

Key palopegteriparatide studies

Palopegteriparatide clinical trials

Is palopegteriparatide approved?

Palopegteriparatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about palopegteriparatide

Related peptides

Sources

Palopegteriparatide

Palopegteriparatide at a glance

What is palopegteriparatide?

The history of palopegteriparatide

Palopegteriparatide structure and chemistry

What palopegteriparatide studies show

Salt, water and minerals

Hormones

Daily life and fitness

Kidneys and bladder

Bones and joints

Memory and thinking

Key palopegteriparatide studies

Palopegteriparatide clinical trials

Is palopegteriparatide approved?

Palopegteriparatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about palopegteriparatide

Related peptides

Sources